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PREFACE
Genetic and genomic approaches to understanding drug
resistance in parasites
EILEEN DEVANEY*
Institute of Infection Immunity and Inﬂammation, University of Glasgow, Bearsden Road, Glasgow G61 1QH
(Received 14 June 2013; accepted 16 June 2013)
Drug resistance is a major challenge in many
infectious diseases including those caused by para-
sites. In the absence of vaccines, treatment and
control of most parasitic diseases will continue to
rely almost exclusively on the use of drugs for the
foreseeable future. Until recently, the paucity of new
drugs for many parasites coupled with the inexorable
spread of resistance heralded a potentially cata-
strophic situation, as exempliﬁed by signiﬁcant
anthelmintic resistance in many parasitic nematodes
of veterinary signiﬁcance. Times may be changing,
however; the London declaration demonstrated a
new commitment from the pharmaceutical industry
at least for neglected tropical diseases (http://www.
unitingtocombatntds.org/), while the increasing
availability of genetic and genomic resources for
many parasites should facilitate the identiﬁcation of
genes involved in resistance and suggest novel
approaches to managing this problem.
Drug resistance is deﬁned as a heritable reduction
in the sensitivity of a parasite population to the
action of a drug. There are many good reasons
for attempting to understand the genetic basis of
resistance: for the development of sensitive and
speciﬁc markers to identify and track drug-resistant
parasites in ﬁeld populations, to facilitate studies
aimed at understanding the origin and spread of
resistance, to determine whether the resistant pheno-
type can be manipulated or reversed, to better
understand the mode of action of some drugs, and
for assessing programmes/treatment schedules aimed
at minimizing the spread of resistance. Furthermore,
if drug resistance could be detected early it might be
possible to eliminate parasites resistant to one drug
before the resistant genotype prevails. Given that the
treatment of most parasitic infections relies on a very
limited pharmacopoeia, preserving the life-span of
existing drugs in the face of increasing levels of
resistance is of great importance.
In this Special Issue of Parasitology, we bring
together seven reviews covering various approaches
to understanding mechanisms of drug resistance in
some of the major parasite species of humans and
animals. Some common themes emerge in these
papers: an important question raised by several
authors is how to distinguish treatment failures
from true resistance. Treatment failures can arise
from many factors other than resistance, including
variation in the strain or isolate of parasite under
study, variation in host pharmacokinetics, variation
in the susceptibility of diﬀerent life-cycle stages to
drug, the impact of infection intensity, the source and
activity of the drug, as well as factors relating to the
suitability and sensitivity of methods used to assess
drug eﬃcacy. These issues only serve to stress the
desirability of developing molecular probes to assess
properly the occurrence and extent of resistance.
Other common themes include: the pros and cons of
the ‘candidate gene’ approach.Many previous studies
on the mechanisms of drug resistance in various
parasite species focused largely on the identiﬁcation
of mutations or single nucleotide polymorphisms
(SNPs) in genes which were predicted either to
be drug targets or to be involved in the uptake,
metabolism or eﬄux of drugs. It is now appreciated
that, at least in some systems, the basis of resistance
is likely to be multigenic, highlighting the desir-
ability of adopting genome-wide approaches. The
new tools being developed such as the various ‘omics’
approaches and the genetic and genomic resources
becoming available for many parasite species will
allow non-assumptive approaches to be adopted to
identify the genetic basis of resistance based on
genome-wide analysis.
Given the continuing devastating impact of
malaria, particularly in sub-Saharan Africa, the issue
of drug resistance remains a priority for research. We
start with a paper onPlasmodium falciparum (Mwangi
and Ranford-Cartwright, 2013), which presents an
historical overviewof anti-malarial drug development
and the spread of resistance. Chloroquine was
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ﬁrst introduced in the 1940s, and resistance in
P. falciparum ﬁrst reported in the 1960s. Since then
chloroquine resistance has spread, so that it nowmore
or less mirrors the distribution of the parasite. While
polymorphisms in speciﬁc genes are associated with
resistance to chloroquine, there is still debate as tohow
resistance arises and whether additional alleles are
involved. Combination therapies are generally con-
sidered to slow down the rate of development of drug
resistance, but the use of artemisinin-based combi-
nation therapies, the ﬁrst-line treatment for uncom-
plicated P. falciparum in many regions of the world,
is now threatened by the emergence of artemisinin
resistance in South East Asia. Recent studies on
artemisinin resistance highlight novel mechanisms
by which parasites can tolerate drug pressure, such as
the apparent ability of ring-stage parasites to enter
a quiescent state in the presence of drug (Witkowski
et al. 2010). This interesting phenotype helps explain
the delayed clearance rate of parasites, a characteristic
of artemisinin resistance.
Vector control via spraying and the use of
insecticide-treated bed nets has had a major impact
on the disease burden attributed to malaria in the
past 20 years. Unfortunately, just as resistance is
widespread to anti-malarial drugs, the same is true for
insecticide resistance in ﬁeld populations of malaria
vectors. Witzig and colleagues (2013) deal with this
subject in their paper on pyrethroid resistance in
Anopheles gambiae. Their contribution highlights
many of the issues surrounding the identiﬁcation of
loci involved in resistance: candidate gene approaches
have been successfully applied to A. gambiae, while
the availability of the genome has identiﬁed a
large number of SNPs that may be associated with
resistance. They describe the use of genetic crosses
between natural ﬁeld populations (rather than lab-
oratory colonies) of A. gambiae to map quantitative
trait loci (QTLs) associated with insecticide resist-
ance and highlight the pros and cons of the various
approaches to identifying genes underlying pyre-
throid resistance.
In their contribution, Alsford et al. (2013) describe
the limitations of the drugs currently available for
treatment of human African trypanosomiasis (HAT)
and Chagas disease, two parasitic infections with
very limited options for chemotherapy. The toxicity
of many of the drugs used to treat HAT impacts on
patient compliance and makes deﬁning resistance,
rather than treatment failure, challenging. Much of
the literature on drug resistance in African trypano-
somes revolves around candidate genes such as drug
transporters, which are known to be altered in some
drug-resistant isolates of Trypanosoma brucei. More
recent eﬀorts to identify genes involved in drug
resistance in trypanosomes have used genome-wide
RNAi approaches. By introducing several modiﬁ-
cations to the standard RNAi methodology, it has
been possible to develop an inducible high-
throughput RNAi screen followed by next generation
sequencing (RIT-seq for RNA interference target
sequencing) to detect T. brucei parasites able to
survive drug treatment. This approach identiﬁes
loss-of-function mechanisms that confer resistance
to the parasite. These studies conﬁrmed the role of
drug transporters in resistance to speciﬁc drugs,
while also identifying a number of novel factors, some
of which would not have otherwise been implicated
in resistance.
Finally for the protozoan parasites, Berg et al.
(2013) describe a numbers of ‘omics’ approaches to
identifying mechanisms of drug resistance in the
Leishmania species. Given the small number of drugs
available to treat leishmaniasis, their review stresses
the desirability of safeguarding the few available
compounds. Leishmania species adopt multiple
mechanisms to survive drug exposure including
sequence polymorphisms in speciﬁc genes and other
modiﬁcations, such as gene ampliﬁcation and vari-
ation in copy number. In addition, as intra-cellular
parasites in the mammalian host, resistance to
antimonial compounds can also involve modiﬁcation
of host cell genes as well as parasite genes. They
summarize recent data from metabolomics studies
and argue for the integration of these approaches
with genomic studies. Importantly, they end with
a discussion of how data arising from such high
tech experiments can be translated to the ﬁeld in
resource-poor settings.
The next two articles by Gilleard (2013) and
Hodgkinson et al. (2013) deal with the ongoing issues
of drug resistance in helminths of veterinary signiﬁ-
cance. Here, nematodes such asHaemonchus contortus
and Teladorsagia circumcincta give the greatest cause
for concern, as resistance is prevalent to all three
classes of widely used anthelmintic. The inability of
anthelmintics to control veterinary species, such as
Haemonchus, threatens the viability of the livestock
industry in some parts of theworld.As the samedrugs
are also used in mass drug administration (MDA)
programmes for human diseases, such as hookworm
infection and onchocerciasis, this inevitably gives rise
to concern as to the long-term sustainability of such
approaches, as highlightedby the failure of ivermectin
treatment inOnchocerca volvulus (Osei-Atweneboana
et al. 2011). As reviewed by Gilleard (2013), research
on parasitic nematodes has suﬀered from a lack of
genetic and genomic resources, a situation that is
beginning to change with the availability of genomic
and transcriptomic sequences from species such as
Haemonchus. In addition, the experimental tract-
ability ofH. contortus, together with a number of novel
resources such as the genetic backcrosses between
well-deﬁned strains of diﬀering drug sensitivity,
demonstrate many of the advantages of using
Haemonchus as an experimental model. In his article,
Gilleard also highlights the desirability ofmonitoring
the integrity of parasite isolates used in diﬀerent
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laboratories around theworld, an important but often
over-looked issuewhen comparing data froma variety
of laboratories. Forward genetic approaches, such as
thebackcross lines inwhich resistance geneshavebeen
introgressed into a susceptible genetic background
and taken through successive generations of crossing
with ivermectin selection, are already providingmuch
useful data. Using microsatellite loci, it was shown
that the backcross progeny were genotypically similar
to the susceptible parent, but phenotypically resistant
to ivermectin. A better understanding of issues such
as population structure and size, together with the
continued generation of tools such as microsatellite
markers and SNPs, all contribute to the potential to
undertake population genetic studies inHaemonchus.
A similar approach has recently been adopted for
the liver ﬂuke Fasciola hepatica, a parasite with an
increasing distribution due to climate change and
livestock movement. As with the other parasites dealt
with in this issue, there are few drugs available for the
treatment of liver ﬂuke and resistance to triclabenda-
zole (TCB), the most widely used of these, is an
increasing problem. The article by Hodgkinson and
colleagues (2013) reviews the current status of TCB
resistance and summarizes the availability of genetic
resources for F. hepatica research. A forward genetic
approach to identifying genes involved in TCB
resistance has been adopted by the authors, based
on the generation of a backcross between TCB-
susceptible and TCB-resistant parasites. Taking
advantage of the life-cycle of F. hepatica, in which
clonal expansion takes place in the snail host, lines
were generated from conﬁrmed TCB-susceptible
and -resistant isolates from UK ﬁeld populations,
the aim being to generate F1 and F2 recombinants for
genetic mapping. A SNP discovery programme and
the identiﬁcation of neutral microsatellite markers
from the draft genome sequence will facilitate the
identiﬁcation of recombinants and, in future studies,
regions of the genome under TCB selection.
The ﬁnal article by Greenberg (2013) deals with
the spectre of praziquantel resistance in schistosomes.
In common with many other helminth parasites of
humans, chemotherapy is based largely on a single
drug, in this case praziquantel, which is frequently
delivered via MDA campaigns. Praziquantel shows
activity against all species of human schistosome and
is relatively inexpensive, and thus is the drug of
choice for control and treatment of this infection.
The degree of resistance to praziquantel in ﬁeld
population of schistosomes remains the subject of
much debate, but there are well-documented cases
of treatment failures and resistant parasites have
been selected in laboratory studies. The widespread
dependency on praziquantel coupled with the fact
that there are few alternative drugs currently on the
market gives cause for concern. Like many other
anthelmintics, the precise mode of action of prazi-
quantel on schistosomes remains unresolved.
Greenberg provides a useful update on the status of
research on drug eﬄux mechanisms, such as the
expression of multi-drug transporters and their
possible association with praziquantel resistance in
ﬂukes, including Schistosoma mansoni. The article
concludes with an overview of the genetic toolkit now
available to address issues such as drug resistance:
the genome sequences for all three species of human
schistosome, the transcriptome data for S. mansoni,
the availability of a genetic map for S. mansoni, the
ability to undertake genetic crosses, the application
of RNAi and transgenesis together set the scene for
major advances in the ﬁeld of schistosome biology.
As is clear from these articles, the scientiﬁc
community has been extremely resourceful in devel-
oping and applying new tools to address the problem
of drug resistance. Technology is on our side, with
the availability and aﬀordability of massively parallel
(or next generation) sequencing, the construction of
genetic maps for several important parasite species
and a variety of genome wide approaches, which
should allow the identiﬁcation of areas of the genome
with signatures of drug selection. In the future, the
emphasis will shift from studies on laboratory isolates
to population genetic studies, such as that recently
reported for P. falciparum. Here regions of the
genome under selection following artemisinin
therapy were identiﬁed using genome-wide ap-
proaches (Cheeseman et al. 2012). For metazoan
parasites with large genomes, techniques such as
Restriction-site AssociatedDNASequencing (RAD-
Seq), a method of reduced representation genome
sequencing (Davey et al. 2011), can be applied to
the genotyping of ﬁeld populations of known drug
sensitivity. While advances in technology oﬀer
enormous opportunities, the success of such methods
is highly dependent on having well-characterized
biological material of known phenotype in relation to
drug resistance. Ultimately, the application of genetic
and genomic tools to the problem of drug resistance
will provide a better understanding of the evolution
and spread of resistance alleles within populations.
These data will be important for designing and
monitoring programmes aimed at restricting the
spread of resistance and preserving the life-span of
the few existing drugs, until alternative control
strategies are available.
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